Cover Image
市場調查報告書

血管炎:開發平台分析

Vasculitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200500
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
血管炎:開發平台分析 Vasculitis - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 94 Pages
簡介

血管內發炎便稱作血管炎。症狀有發燒、頭痛、疲勞感、體重減輕、全身疼痛、皮疹、手腳脈搏消失等。因素有B型肝炎、C型肝炎等感染疾病、血癌、類風濕性關節炎和紅斑性狼瘡、硬皮症等所謂的免疫系疾病等。

本報告提供血管炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

血管炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • AnGes MG, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Aprogen, Inc.
  • ChemoCentryx, Inc.
  • Clearside BioMedical, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hemostemix Ltd
  • Hospira, Inc.
  • K-Stemcell Co., Ltd.
  • Panacea Biotec Limited
  • Pluristem Therapeutics Inc.
  • Sandoz Inc.
  • XOMA Corporation

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACP-01
  • belimumab
  • beperminogene perplasmid
  • blisibimod
  • CCX-168
  • gevokizumab
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • rituximab biosimilar
  • Stem Cell Therapy for Cardiovascular Deseases
  • tocilizumab
  • triamcinolone acetonide
  • Vascostem

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8258IDB

Summary

Global Markets Direct's, 'Vasculitis - Pipeline Review, H2 2016', provides an overview of the Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vasculitis
  • The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
  • The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vasculitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vasculitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vasculitis Overview
  • Therapeutics Development
    • Pipeline Products for Vasculitis - Overview
    • Pipeline Products for Vasculitis - Comparative Analysis
  • Vasculitis - Therapeutics under Development by Companies
  • Vasculitis - Therapeutics under Investigation by Universities/Institutes
  • Vasculitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Vasculitis - Products under Development by Companies
  • Vasculitis - Products under Investigation by Universities/Institutes
  • Vasculitis - Companies Involved in Therapeutics Development
    • AnGes MG, Inc.
    • ChemoCentryx, Inc.
    • Cipla Ltd.
    • Coherus BioSciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Hemostemix Ltd
    • Johnson & Johnson
    • K-Stemcell Co., Ltd.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sandoz International GmbH
    • Teijin Pharma Limited
  • Vasculitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-1355 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirukumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Thromboangiitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vasculitis - Dormant Projects
  • Vasculitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 06, 2016: Phase III study shows Roche's Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)
      • May 30, 2016: DCGI Gives Limited Approval to Market FIRST Allogeneic Cell Therapy Product in India Stempeutics puts India on the World map of Regenerative Medicine
      • Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
      • Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans
      • Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel'
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
      • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
      • Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis
      • Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal
      • May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress
      • Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis
      • Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vasculitis, H2 2016
  • Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Vasculitis - Pipeline by AnGes MG, Inc., H2 2016
  • Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Vasculitis - Pipeline by Cipla Ltd., H2 2016
  • Vasculitis - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Vasculitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Vasculitis - Pipeline by Hemostemix Ltd, H2 2016
  • Vasculitis - Pipeline by Johnson & Johnson, H2 2016
  • Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2016
  • Vasculitis - Pipeline by Panacea Biotec Limited, H2 2016
  • Vasculitis - Pipeline by Pfizer Inc., H2 2016
  • Vasculitis - Pipeline by Sandoz International GmbH, H2 2016
  • Vasculitis - Pipeline by Teijin Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vasculitis - Dormant Projects, H2 2016
  • Vasculitis - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Vasculitis, H2 2016
  • Number of Products under Development for Vasculitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top